A randomized, double-blind, placebo-controlled study on the effects of grow by WONDERLAB™ Mengzhang No.1™ Calcium, Zinc, and L-Lysine Flavored Complex Beverage alone and in combination with grow by WONDERLAB™ Stage 3 Probiotics on height growth, sleep quality, and gastrointestinal function in children aged 6-12 years

A Randomized, Double-Blind, Placebo-Controlled Study on the Effects of WonderLab "Mengzhang No.1™" Calcium, Zinc, and L-Lysine Flavored Complex Beverage Alone and in Combination with Phase 3 "Little Yellow Bottle" Probiotics on Height Growth, Sleep Quality, and Gastrointestinal Function in Children Aged 6-12 Years

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2600118135

Enrollment

Unknown

Registered

2026-02-02

Start date

2026-02-02

Completion date

Unknown

Last updated

2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy children aged 6–12 years

Interventions

combined intervention group:Calcium, Zinc and L-Lysine Flavored Complex Beverage + Stage 3 Probiotics

Placebo Control Group:Placebo of Simulated Calcium, Zinc and L-Lysine Flavored Complex Beverage + Placebo of Simulated Stage 3 Probiotics

Calcium-Zinc-Lysine beverage intervention group:Calcium, Zinc and L-Lysine Flavored Complex Beverage + Placebo of Simulated Stage 3 Probiotics

Eligibility

Sex/Gender

All

Age

6 Years to 12 Years

Inclusion criteria

Inclusion criteria: 1. Gender: no restriction; aged 6–12 years old at the time of signing the informed consent form; 2. No history of systemic diseases, nutritional disorders, or other conditions that may affect height growth, sleep quality, gastrointestinal function, or calcium metabolism. 3. The subjects and/or their parents/guardians agree to participate in this study and voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. A history of major diseases (including heart, liver, kidney, nervous system, systemic infection, and mental disorders, etc.); 2. Use of drugs affecting growth or gastrointestinal function (e.g., growth hormone, sex hormones, thyroid hormones, laxatives/antidiarrheals, proton pump inhibitors, etc.) within the past month; 3. Known history of severe atopy, or hypersensitivity or intolerance to the study products or their excipients; 4. Participation in other drug clinical trials within 3 months prior to signing the informed consent form; 5. Poor expected medication compliance, or inability of parents/guardians to cooperate with the fulfillment of study requirements; 6. Any other circumstances that, in the investigator’s judgment, make the subject unsuitable for participation in this study.

Design outcomes

Primary

Measure	Time frame
Change in height;	—

Secondary

Measure	Time frame
Children's Sleep Habits Questionnaire (CSHQ) Score;Appetite Visual Analog Scale (VAS);Change in height;Metagenomic Sequencing of Intestinal Flora;Gastrointestinal Symptom Rating Scale (GSRS);	—

Countries

China

Contacts

Public ContactSitao Li

The Sixth Affiliated Hospital,Sun Yat-sen University

Lisit@mail.sysu.edu.cn+86 181 2275 0208

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026